Published in Pharma Investments, Ventures and Law Weekly, September 24th, 2006
KOS-953 is named tanespimycin and KOS-1022 is named alvespimycin hydrochloride. The compound names have been adopted by the United States Adopted Names Council and the World Health Organization.
Tanespimycin is the most advanced Hsp90 inhibitor in clinical trials. The compound is in a phase Ib trial in combination with Velcade for multiple myeloma, and is in a phase I trial as a single agent in multiple myeloma. Tanespimycin is also being evaluated in a phase II combination trial with Herceptin for breast cancer, and in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.